Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients

Prostate

Volumn 67, Issue 1, 2007, Pages 1-7

  Sciarra, Alessandro ^a,b   Lichtner, Miriam ^a   Autran Gomez, AnnaMaria ^a   Mastroianni, Claudio ^a   Rossi, Raffaella ^a   Mengoni, Fabio ^a   Cristini, Cristiano ^a   Gentilucci, Alessandro ^a   Vullo, Vincenzo ^a   Di Silverio, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Dendritic cells; Gleason score; Immunotherapy; Prostate cancer; PSA

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOFLUOROMETRY; DENDRITIC CELL; FLOW CYTOMETRY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOID CELL; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CELL COUNT; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MYELOID CELLS; PROSTATIC NEOPLASMS;

EID: 33845741035     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20431     Document Type: Article

References (20)

1. Tjoa B, Lodge AP, Salgaller LM, Boynton LA, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA J Clin 1999;49:117-128.
2. Small JE, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clinc Oncol 2000;123:3894-3903.
3. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clinic Invest 2002;109:409-417.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
5. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-161.
6. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schimitz J, Hart DJ. Characterization of human blood dendritic cells subsets. Blood 2002;100(13):4512-4520.
7. Ragde H, Cavanaghi WA, Tjoa B. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004;172:2532-2538.
8. Manna PP, Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol 2002;72:312-320.
9. Banchereau J, Palucka K. Dendritic cells as therapeutic vaccines against cancer. Nat Med 2005;5:296-306.
10. Arroyo JC, Gabilondo F, Llorente L, Meraz-Rios MA, Torres-Sanchez C. Immune response induced in vitro by CD 16-and DC16+ monocyte derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol 2004;24:86-94.
11. Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004;53:453-460.
12. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C. Reduced blood CD 123+(Lymphoid) and CD 11 c+ (Myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001;98(10):3016-3021.
13. Lichtner M, Rossi R, Mengoni F, Vignoli S, Colacchia B, Massetti AP, Kamga I, Hosmalin A, Vullo V, Mastroianni CM. Circulating dendritic cells and interferon-α production in patients with tuberculosis: Correlation with clinical outcome and treatment response. Clin Experimen Immunol 2006;143:329-337.
14. Vuckovic S, Gardiner D, Field K, Champan GV. Monitoring dendritic cells in clinical practice using a new whole blood single-platform Tru Count™ assay. JIM 2004;284:73-87.
15. De Orange A, Jeganthesan M, Blachère NE, Frank MO, Scher HI. Effective antigen cross presentation by prostate cancer patients' dendritic cells: Implications for prostate cancer immunotherapy. Prostate cancer and Prostatic Dis 2004;7:63-72.
16. Tjoa BA, Lodge PA, Salgaller ML, Boynton LA, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49:117-128.
17. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shuring GV, Huland E. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001;46:68-75.
18. Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 2003;170:2026-2030.
19. Tschoep K, Manning TC, Harlin H, George C, Johnson M, Gajewski TF. Disparate functions of immature and mature human myeloid dendritic cells: Implications for dendritic cell-based vaccines. J Leukoc Biol 2003;74:69-80.
20. Wilkinson R, Kassianos AJ, Swindle P, Hart DNJ, Radford KJ. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006;66(2):180-192.